China Pharma Holding (STU:XQJ) Growth Rank: 1 (As of Sep. 22, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:XQJ China Pharma Holding Inc STU:XQJ
29 GF Score
Price €26.80
GF Value €5.99
! 4 Warning Signs
View Full Analysis

What is China Pharma Holding Growth Rank?

China Pharma Holding STU:XQJ 29 Growth Rank is 1 as of Sep. 22, 2026, which is 50% below its 10-year median of 2.00. GuruFocus rates STU:XQJ with a GF Score™ of 29/100 and a GF Value™ of €5.99. The stock has 4 warning signs investors should review.

China Pharma Holding has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

China Pharma Holding Growth Rank Related Terms

STU:XQJ vs IXHL, MRMD, RMTI: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Pharma Holding Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Growth Rank distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Growth Rank falls into.


STU:XQJ
29GF Score
China Pharma Holding Inc STU:XQJ
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
China Pharma Holding (STU:XQJ) has a Growth Rank of 1 as of Sep. 22, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on China Pharma Holding and its competitors. This is 50% below median its historical median of 2.00. Over the past decade, China Pharma Holding's Growth Rank has ranged from 1.00 to 7.00.
Is China Pharma Holding's Growth Rank too high?
China Pharma Holding's current Growth Rank of 1 is 50% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. Overall, China Pharma Holding has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Growth Rank compare to IXHL and MRMD?
China Pharma Holding's Growth Rank of 1 can be compared against companies in the Drug Manufacturers industry. Historically, China Pharma Holding's own Growth Rank has ranged from 1.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on China Pharma Holding and its competitors. China Pharma Holding's current Growth Rank is 1, which is 50% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current Growth Rank of 1. The stock's GF Value™ is €5.99, compared to a current price of €26.80 — trading 347.4% above its estimated fair value. The current Growth Rank is 1, which is 50% below median its 10-year median of 2.00. China Pharma Holding's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current Growth Rank is 1 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Pharma Holding (STU:XQJ) Overvalued in 2026?

Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued. The current stock price of €26.80 is trading 347.4% above its estimated GF Value™ of €5.99.

Key valuation signals for STU:XQJ:

  • Growth Rank: 1 (50% below median its 10-year median of 2.00)
  • GF Value™: €5.99 vs. price of €26.80 (347.4% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Pharma Holding Business Description

Other Exchanges CPHI:USA
Address No. 17, Jinpan Road, Second Floor, Jiahai Building, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
29GF Score

Get the complete analysis for STU:XQJ

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.80
Price
€5.99
GF Value